10086924EPIC DISCO: Enhanced Precision Immunomics Cancer antigen DISCOveryClosedCollaborative R&DInnovate UKInfinitopes is a **Cancer Research UK (CRUK)-led spinout from Oxford University**. We are also backed by Cancer Research Institute NY, and leading British investors, Octopus Ventures, Kindred and Meltwind. Emerging from a decade of research excellence, we bring together **international scientific and medical leaders across oncology, immunology and vaccine development**. Our first generation of vaccines deliver **80% survival and the prevention of metastases**, in preclinical trials. This is important because metastases have been shown to cause 70-90% of cancer deaths. With Innovate UK's support, we are **progressing our lead therapy into an exciting proof of concept human clinical trial**, to protect patients after surgical resection of their tumour. Infinitopes is able to deliver these unusually high levels of protection, because our technologies combine **accurate tumour target identification with high efficiency delivery, to durably stimulate patients' immunity against their cancers**. New high sensitivity technologies are emerging with the **potential to revolutionise tumour target discovery**. Our Enhanced Precision Immunomics Cancer antigen DISCOvery **(EPIC DISCO) project proposes to conduct experimental development, to systematically evaluate and improve the key steps in antigen discovery**, in order to leverage maximal benefit from these new systems. We will also build highly **accurate immunopeptidome tumour maps for 4-5 target indications, including common cancers of childhood and adolescence, sarcoma and glioblastoma, and adult cancers** of high unmet need. This project cements Infinitopes' **leadership of immuno-oncology therapeutics, directly supporting tens of new highly skilled jobs**, where we can continue to contribute to Britain's world leading life sciences ecosystem, while unlocking substantial partnerships with Big Pharma and biotech collaborators. Infinitopes' mission is to progressively enhance our discovery and vector technology platforms, **to enable precisely targeted treatment of high unmet cancers, affordably and without side effects**.